CD79B and acute lymphoblastic leukemia: Yet, the observation of tumor immune-escape via downregulation of the target-antigen, for example, CD19 motivates the identification of novel immunotherapy targets.13 We show the presence of CD79b on the surface of diagnostic patient samples of different BCP-ALL subgroups.